New diabetes drug tested in people with kidney issues
NCT ID NCT06370819
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 1 study tested how different levels of kidney function affect the processing of a single dose of the experimental drug NNC0519-0130. Thirty-six adults with type 2 diabetes and varying kidney function (normal to severely impaired) received one injection. Researchers measured drug levels in the blood to see if kidney problems change how the drug is handled, which could guide future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0519-0130
What this could lead to
If successful, this study could help determine the right dose of NNC0519-0130 for people with type 2 diabetes who also have kidney problems.
What could go wrong
This is an early, small study (36 participants) that only looks at drug levels in the blood, not at actual treatment effects or long-term safety. Results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117, Germany